摘要
This review discussed experimental mouse models used in the pre-clinical study of liver fibrosis regression,a pivotal process in preventing the progression of metabolic dysfunction-associated steatohepatitis to irreversible liver cirrhosis.These models provide a valuable resource for understanding the cellular and molecular processes underlying fibrosis regression in different contexts.The primary focus of this review is on the most commonly used models with diet-or hepatotoxin-induced fibrosis,but it also touches upon genetic models and mouse models with biliary atresia or parasiteinduced fibrosis.In addition to emphasizing in vivo models,we briefly summarized current in vitro approaches designed for studying fibrosis regression and provided an outlook on evolving methodologies that aim to refine and reduce the number of experimental animals needed for these studies.Together,these models contribute significantly to unraveling the underlying mechanisms of liver fibrosis regression and offer insights into potential therapeutic interventions.By presenting a comprehensive overview of these models and highlighting their respective advantages and limitations,this review serves as a roadmap for future research.
基金
MS is supported by the European Foundation for the Study of Diabetes and the Leiden University Fund.PCNR is supported by The Netherlands Cardiovascular Research Initiative CVON-GENIUS-2 supported by the Dutch Heart Foundation.
作者简介
Corresponding author Milena Schönke,Division of Endocrinology,Department of Medicine,Leiden University Medical Center,Albinusdreef 2,2333BG Leiden,The Netherlands.ORCID:https://orcid.org/0000-0003-2030-6958.Tel:+31-640131148,E-mail:m.schoenke@lumc.nl。
